Genetic susceptibility to neuroblastoma

Area of Science:

• Oncology
• Genetics
• Developmental Biology

Background:

• Neuroblastoma, a complex neoplasm of the sympathetic nervous system, previously had an undefined genetic basis.
• Recent discoveries have identified specific gene mutations contributing to familial and sporadic forms of the disease.

Purpose of the Study:

• To elucidate the genetic underpinnings of neuroblastoma.
• To identify novel therapeutic targets and understand disease heterogeneity.

Main Methods:

• Analysis of familial neuroblastoma cases to identify causative mutations.
• Discovery of gain-of-function mutations in the ALK receptor tyrosine kinase gene.
• Identification of inactivating mutations in the PHOX2B gene.
• Genome-wide association studies (GWAS) in large neuroblastoma cohorts to detect common and rare polymorphisms.

Main Results:

• Gain-of-function mutations in ALK are a major cause of familial neuroblastoma, with identical somatic mutations found in sporadic cases, establishing ALK as a therapeutic target.
• Inactivating mutations in PHOX2B, a neural crest development regulator, were identified in a subset of familial neuroblastomas.
• Heritable mutations account for less than 10% of neuroblastoma cases.
• GWAS identified common and rare polymorphisms strongly associated with neuroblastoma risk.

Conclusions:

• While ALK and PHOX2B mutations are significant, they explain a minority of neuroblastoma cases, indicating the involvement of other genetic factors.
• Further genetic investigations, including ongoing resequencing efforts, are crucial to fully define the genetic landscape of neuroblastoma and improve patient outcomes.